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Abstract
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) dates back to thousands of 
years when man used natural sources of these agents in a lot of pain and inflammatory 
conditions. The tone for modern day discovery and use of NSAIDs was set with the dis-
covery of aspirin. Today in addition to aspirin, a host of other NSAIDs of varying potency 
and efficacy is employed in the management of pain and inflammatory conditions. This 
chapter looks with key interest in the existing and evolving role of NSAIDs in therapeu-
tics with emphasis on the current insights into their mechanism of action and side effect 
profiles associated with its use in pain and inflammation as well as its potential therapeu-
tic benefits in cancer chemotherapy.
Keywords: nonsteroidal anti-inflammatory drugs, inflammation, cyclooxygenase, pain, 
fever
1. Introduction
The history of nonsteroidal anti-inflammatory drugs (NSAIDs) dates as far back as thousands 
of years with Hippocrates and other physicians prescribing the willow bark for a wide range 
of conditions [1]. The tone for the modern era of NSAIDs was, however, set by identifying 
salicin as the willow plant’s active ingredient and the subsequent introduction of acetylsali-
cylic acid by the Bayer Company about two centuries later [2]. Today in addition to aspirin, 
nonselective NSAIDs, such as piroxicam, mefenamic acid, diclofenac, naproxen, and  selective 
 cyclooxygenase-2 (COX-2) inhibiting NSAIDs, such as celecoxib and rofecoxib, remain 
 mainstays of pain and inflammatory disorder therapy.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
NSAIDs remain one of the most consumed drugs either by prescription or over-the-counter [3]. 
Their fever relieving effect has been well documented since their discovery and they have proven 
effective over the years in controlling pain and inflammatory conditions. It is particularly effec-
tive in acute and chronic orthopedic pain (osteoarthritis, ankylosing spondylitis, and rheumatoid 
arthritis) and postsurgical pain [4]. While these represent the traditional uses of NSAIDs, studies 
have pointed to their potential in Alzheimer’s [5], cancer [6], and Parkinson’s disease [7]. Most 
of these studies exploit the benefits of controlling the underlying inflammatory mechanisms of 
these diseases.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of therapeutic agents with 
diverse structural and pharmacodynamics profiles but similar mode of action. Broadly, 
NSAIDs are grouped into aspirin and nonaspirin NSAIDs. Despite similarities in their mech-
anism of action and toxicity profiles, they differ slightly in the manner they each interact 
with the cyclooxygenase enzyme [8]. A more popular classification, however, is based on 
structural differences and similarities [9]. They are grouped as follows: salicylates (aspirin), 
aryl alkanoic acids (diclofenac, indomethacin, nabumetone, sulindac), 2-arylpropionic acids 
or  profens (ibuprofen, flurbiprofen, ketoprofen, and naproxen), n-arylanthranilic acids or 
fenamic acids (mefenamic acids, meclofenamic acid, pyrazolidine derivatives, e.g., phenylbu-
tazone),  oxicams (piroxicam, meloxicam), and sulfonamides (nimesulide).
2. Mechanism(s) of NSAIDs action
2.1. COX and COX inhibition
There is overwhelming evidence pointing to the inhibition of cyclooxygenase enzyme as the 
main mechanism of NSAIDs’ analgesic, antipyretic, and anti-inflammatory properties. Since 
the characterization of this mechanism by Vane for aspirin [10], other drugs in this class have 
proven consistent this mechanism. This is surprising considering the differences in struc-
tures of the individual drugs as described above. Cyclooxygenase (COX) inhibition and the 
resulting inhibition of prostaglandin and other eicosanoid synthesis mitigate pain, fever, and 
inflammation. The cyclooxygenase (COX) enzyme also known as prostaglandin endoperox-
ide H synthase (PGHS) exists in two isoforms: PGHS-1 or COX-1 and PGHS-2 or COX-2. 
There is a significant structural distinction between the two, with only 60% homology [11]. 
Although encoded by different genes, both isoforms are membrane-bound glycoproteins that 
catalyze the formation of prostanoid from arachidonic acid [12].
COX-1 is expressed constitutively in most mammalian cells and tissues such as seminal 
vesicle, platelets, and endothelium. In quiescent conditions, it performs ongoing regulatory 
functions referred to as “housekeeping duties.” Prostaglandins produced by COX-1 activity 
perform functions such as gastro and renal protection, macrophage differentiation, platelet 
aggregation, and mucus production [3, 13]. In inflammatory conditions, molecular studies 
have demonstrated that COX-1 mRNA and protein expression do not change, confirming 
their limited role in the inflammatory process [14]. COX-1, however, remains both experimen-
tally and clinically relevant due to the adverse effects triggered by the nonselective inhibition 
of cyclooxygenase enzymes by some NSAIDs.
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COX-2 is an inducible enzyme called upon by tissue injury and other stimuli such as lipopolysac-
charide (LPS), interleukin-1, and tumor necrosis factor alpha (TNFα) [15, 16]. It is active at injury 
sites and in a variety of tissues such as the vascular endothelium, and rheumatoid synovial endo-
thelial cells mediating inflammatory, pain, fever, and carcinogenic responses [17, 18]. A manifold 
increase in COX-2 levels occurs in inflammatory processes triggering an increased synthesis of 
pro-inflammatory prostaglandins. Initially thought of as exclusively inducible in nature, studies 
have shown COX-2 has some constitutive or regulatory roles. Housekeeping duties in reproduc-
tion, renal physiology, bone resorption, and neurotransmission have been documented [19, 20].
Indeed studies have shown that both isotypes are constitutive and inducible depending on the 
physiological conditions [21, 22]. COX-3, a third isotype, has been identified [23]. Its function, 
distribution, and role in NSAIDs mechanisms are still uncertain and subject of debate [24].
2.2. Pain, fever, and inflammation
The arachidonic acid pathway is central to inflammatory responses and consequently the 
mechanism of action of NSAIDs. Prostanoids, the end product of this pathway, performs a 
wide range of physiological functions.
NSAIDs are largely thought of as inhibitors of peripheral pain though several works in litera-
ture point to a potential and significant central analgesic activity. At the periphery, a host of 
mediators occurs to trigger nociception in response to physical, chemical, or electrical stimuli. 
Prostaglandins act synergistically with other mediators to sensitize nociceptors [10, 25]. Some 
NSAIDs have exhibited central analgesic effects in several animal models of pain. This is attrib-
uted to disruption of synthesis of central prostaglandins and other modulators in the nocicep-
tive pathway. Arguments in favor of central activity stem from studies showing the inhibitory 
effect of NSAIDs on N-methyl-D-aspartate (NMDA) receptor activation-induced prostaglan-
din expression in cerebrospinal fluid [26] and antinociceptive effect of spinally administered 
ibuprofen [27] among others. A classic study by Hunskaar [28] showed overlapping time-effect 
relationship for aspirin and morphine in the first phase of formalin-induced pain response; 
a feature highly indicative of central activity.
NSAIDs have proven effective in inflammatory conditions such as arthritis, acute trauma, 
and pain associated with inflammation. Inflammatory mediators at injury site mediate 
vasodilation extravasation of protein exudates and nociception. Here, prostaglandins that 
are key players in this process are inhibited. Though COX inhibition is maintained as the 
main mechanism for the anti-inflammatory activity of NSAIDs, other mechanisms loosely 
referred to as non-COX mechanisms have been reported in the literature. NSAIDs are docu-
mented to have the suppressive effect in nuclear factor (NF)-κB, a transcription factor for 
pro-inflammatory proteins such as chemokines, adhesion molecules, and cytokines. NSAIDs 
also exhibit some suppression of activator protein 1, membrane stabilizing, and inhibition of 
reactive oxygen species (ROS) production [29–31]. Although these are believed to contribute 
at a molecular level, it is unclear how they directly aid in the clinical benefits of NSAIDs.
NSAIDs relieve fever by inhibiting COX-mediated prostaglandin synthesis. Upon exposure 
to external pyrogens, mostly pathogen-associated molecular patterns (lipopolysaccharide, 
 peptidoglycan, viral RNA, etc.), cells of the innate immune system respond by releasing 
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endogenous pyrogens to induce pyrexia. Circulating interleukin-1, interleukin-6, and TNFα 
gets to the brain and induced the synthesis of prostaglandin via the cyclooxygenase in the 




) binds to an EP-3 recep-
tor of the endothelium of the hypothalamus to reset the body’s thermoregulation. An ensu-
ing physiological process occurs to attain this set temperature. NSAIDs disrupt this process 
by COX inhibition and therefore have proven useful in curbing the harmful effects of high 
and persistent temperatures. It is important to note that they have no effect on normal body 
temperature or atypical rise in temperature such as malignant hyperthermia and heat stroke. 
Mechanisms in these cases are independent of the COX/prostaglandin inflammatory pathway.
2.3. Structure and mechanisms
Current studies have made it possible to understand the structural basis of both nonselective 
cyclooxygenase inhibition and COX-2 selective inhibition and the variations in individual 
NSAID’s interactions with COX. The catalytic site of COX-1 is long narrow hydrophobic chan-
nel spanning from the membrane-binding domain to the enzyme core. The threshold of the 
channel is made up of polar groups such as Arg120 and Glu524. NSAIDs bind at the upper 
portion of this channel specifically at a region near TYR385 and ARG120. Acidic NSAIDs, for 
instance, interact with ARG120 via hydrophobic and electrostatic forces [32].
While aspirin for instance irreversibly inhibits the COX enzyme by covalently modifying it 
active Ser529 [10], other NSAIDs such as ibuprofen and naproxen bind reversibly [33]. Studies 
by Kurumbail et al. [34] revealed a COX-2 3D structure closely resembling COX-1. An extra 
pocket in the COX-2 catalytic site, however, is created by the valine replacements at positions 
523 and 434 (occupied by isoleucine in COX-1). This alteration in structure, among others, is 
exploited in the design of COX-2 selective drugs.
2.4. H
2
S-releasing derivatives of anti-inflammatory drugs
NSAIDs, including selective COX-2 inhibitors, are able to stimulate adherence of leukocytes 
to the vascular endothelium in the mesenteric circulations [35–38] and that has been strongly 
associated with NSAID-induced gastric damage [37–39]. With studies pointing to the ability 
of H
2
S donors to suppress leukocyte adherence, it would have been expected that an H
2
S-
releasing NSAID would not induce leukocyte adherence and will be devoid of the gastric 
damaging property of NSAIDs. This is actually the case and was realized with studies con-
ducted employing H
2
S-releasing derivative of diclofenac (ATB-337) on leukocyte adherence 
and gastric mucosal integrity in rat [40]. The diclofenac derivative did not stimulate leukocyte 
adherence and also not elevate lymphocyte function-associated antigen 1 (LFA-1) or intercel-
lular adhesion molecule 1 (ICAM-1), as was observed in diclofenac; also, it did not cause gas-
tric damage [41]. The H
2
S-releasing diclofenac, however, did not significantly inhibit gastric 
prostaglandin synthesis and systemic COX-1 activity [40]. Similar profile in activity was also 
observed in the H
2
S-releasing derivative of indomethacin (ATB-343).
H
2
S-releasing derivatives of NSAIDs have also been established to reduce infiltration of 
leukocytes in models of inflammation. A diclofenac derivative has been shown to reduce 
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LPS-induced infiltration of neutrophils into the lung and liver [41]; also an H
2
S-releasing 
derivative of mesalamine profoundly reduced granulocyte infiltration in a mouse model of 
colitis [42] with effect significantly greater than that observed in the parent molecules in each 
case. H
2
S-releasing diclofenac was also realized to be more potent than diclofenac in reducing 
paw edema in the carrageenan-induced paw edema model in rat.
The upregulation in TNF-α and COX-2 expression in the rat stomach [43, 44] by NSAIDs is 
not observed in the H
2
S-releasing derivatives of NSAIDs despite their ability to cause marked 
suppression of gastric prostaglandin synthesis [40]. Moreover, these derivatives inhibit endo-
toxin-induced NF-κB activation and the associated increase in plasma TNF-α, nitrate, and 
nitrite [41].
2.5. Antitumor action of NSAIDs
NSAIDs have many effects that might contribute to chemoprevention of cancers such as colorec-
tal cancer (CRC). This mode of prevention can be either COX-dependent or COX-independent 
which can be synergistic at different steps of this multistep process [45] with evidence for replace-
ment of adenomatous polyposis coli (APC) function by NSAIDs. In this direction, sulindac and 
indomethacin have been shown to inhibit tumorigenesis through  inhibition of peroxisome prolif-
erator-activated receptor delta (PPARδ), a gene that is normally regulated by APC [46]. Currently, 
alterations of the COX-2-related pathways are in primary focus [47].
With NSAIDs being transcriptional inhibitors of COX-2 expression [48], these agents might 
selectively inhibit the induction of apoptosis in human intestinal stem cells with aberrant Wnt 
signaling [49]. The most compelling evidence of the possible chemopreventive action of some 
NSAIDs was the finding that aspirin reduces the risk of CRC in individuals with elevated 
COX-2 expression but not in those without [50] with associated reduced mortality [51], in 
an observational study. This was however experimentally confirmed when data affirmed the 
involvement of prostaglandins and nonprostaglandin COX-2 products were central to the 
development of CRC [52].
Measurable levels of NSAID-activated gene-1 (NAG-1) were detected in an NSAID-treated 
human CRC cell line. NAG-1 belongs to the transforming growth factor beta (TGFβ)-
superfamily of growth factors and plays a significant role in apoptosis and tumorigenesis. 
In the CRC cells, NAG-1 expression positively correlates apoptosis and inversely correlates 
with COX-2 expression, with NAG-1 upregulation linked with NSAID administration in a 
Prostaglandin-independent manner [53]. Overexpression of NAG-1 in APC-mutated Min/+ 
mice results in reduced tumorigenesis. Interestingly, however, high COX-2 expression in 
colorectal tumors is associated with decreased expression of NAG-1, suggesting a  reciprocal 
relationship [54]. It is henceforth being speculated that high levels of COX-2 in  colorectal 
tumors suppress the expression of NAG-1; hence induction of NAG-1 by NSAIDs might 
 contribute to the chemopreventive action of these agents [55].
Aspirin has a unique property of acetylating COX-2, which is not seen in other NSAIDs. 
This switches COX-2 from synthesizing prostaglandins (PGE
2





), a 5-lipoxygenase catalyzed reaction. 15-epi-lipoxin-A
4
 is 
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 anti-inflammatory as well as anti-proliferative on carcinoma cells [56]. This effect of aspirin is 
seen at low antiplatelet doses with one study with 75 mg/day for 10 days not only reducing 
PGE
2
 formation and white cell accumulation in inflamed tissues but also significantly increas-
ing local lipoxin production [57]. This establishes that the anticancer potential of aspirin may 
be due to lipoxin production.
Several studies also point to COX-2 independent actions may also play a role in apoptosis and 
such pathways have been realized to be sensitive to NSAIDs. Not all human CRCs express 
COX-2 and produce prostaglandins [58, 59]. However, the potency of NSAIDs to inhibit pro-
liferation is similar to COX-2 producing CRC [60]. This is suggestive of the fact that the antitu-
mor actions of NSAIDs are not necessarily via inhibition of COX-2 or prostaglandin formation 
[45, 59]. Sulindac reduces the number of aberrant crypt foci and adenomas in patients under 
conditions when etodolac, COX-2 inhibitor, was ineffective [61]. Moreover, sulindac was also 
found to significantly increase NAG-1 even in COX-2-deficient tumor cell lines [53].
The potential COX-2-independent mechanism of NSAIDs’ antineoplastic action includes 
downregulation of proto-oncogenes, such as c-myc, and transcriptional factors such as 
PPARδ, NF-κB, prostate apoptosis response-4 (PAR-4), and Bcl-2. The most recent therapeutic 
approach therefore entails combining NSAIDs and epidermal growth factor (EGF) receptor 
inhibitors in chemoprevention of CRC [62].
3. Conclusion
The therapeutic importance of NSAIDs in the management of acute and chronic pain and 
inflammation cannot be overemphasized. Also with the emergence of their therapeutic bene-
fits in cancers, it is worth chronicling its pharmacological profile, specifically their established 
and expected mechanistic pathways of eliciting their activity. With promising outcomes in 
the experimental studies with improved gastrointestinal effects associated with modified 
NSAIDs and potential anticancer activity of NSAIDs, we strongly believe there is more to 
NSAIDs than we currently know. This chapter will henceforth give an insight into what is 
known and what could be possibly done in advancing the therapeutic potentials of NSAIDs 
beyond the management of pain and inflammation as we know.
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